Cellebrite DI Ltd. (NASDAQ:CLBT) Receives Average Rating of “Buy” from Analysts

Shares of Cellebrite DI Ltd. (NASDAQ:CLBT) have been given an average recommendation of “Buy” by the seven ratings firms that are currently covering the firm, Marketbeat Ratings reports. Seven analysts have rated the stock with a buy recommendation. The average 1 year price objective among brokers that have covered the stock in the last year is $23.43.

A number of equities research analysts have recently issued reports on CLBT shares. JPMorgan Chase & Co. boosted their target price on Cellebrite DI from $24.00 to $28.00 and gave the stock an “overweight” rating in a research report on Tuesday, February 11th. Lake Street Capital boosted their price objective on Cellebrite DI from $17.00 to $26.00 and gave the stock a “buy” rating in a report on Friday, February 14th. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $28.00 price objective on shares of Cellebrite DI in a research note on Wednesday, April 2nd.

Hedge Funds Weigh In On Cellebrite DI

Large investors have recently made changes to their positions in the business. State Street Corp grew its position in Cellebrite DI by 7.3% during the third quarter. State Street Corp now owns 443,700 shares of the company’s stock valued at $7,472,000 after purchasing an additional 30,052 shares in the last quarter. Y Intercept Hong Kong Ltd grew its holdings in shares of Cellebrite DI by 35.5% during the 3rd quarter. Y Intercept Hong Kong Ltd now owns 19,510 shares of the company’s stock valued at $329,000 after acquiring an additional 5,113 shares in the last quarter. Barclays PLC increased its stake in shares of Cellebrite DI by 29.1% in the third quarter. Barclays PLC now owns 263,657 shares of the company’s stock worth $4,439,000 after acquiring an additional 59,395 shares during the last quarter. Tidal Investments LLC raised its holdings in shares of Cellebrite DI by 59.3% during the third quarter. Tidal Investments LLC now owns 104,478 shares of the company’s stock worth $1,759,000 after acquiring an additional 38,887 shares in the last quarter. Finally, Lord Abbett & CO. LLC acquired a new stake in Cellebrite DI during the third quarter valued at $11,523,000. Institutional investors and hedge funds own 45.88% of the company’s stock.

Cellebrite DI Price Performance

NASDAQ CLBT opened at $19.03 on Thursday. Cellebrite DI has a 12 month low of $10.25 and a 12 month high of $26.30. The company has a market capitalization of $4.56 billion, a P/E ratio of -13.69, a PEG ratio of 4.27 and a beta of 1.44. The company’s 50 day simple moving average is $19.23 and its 200 day simple moving average is $20.02.

Cellebrite DI (NASDAQ:CLBT) last posted its quarterly earnings results on Thursday, February 13th. The company reported $0.07 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.10 by ($0.03). Cellebrite DI had a negative net margin of 70.54% and a positive return on equity of 58.70%. On average, analysts anticipate that Cellebrite DI will post 0.3 earnings per share for the current year.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.